AT247 ultra-rapid insulin
Arecor Therapeutics
Arecor's U100 ultra-rapid insulin formulation, designed to accelerate absorption after injection or pump delivery and better match meal physiology. Early phase 1 and pump-use studies are positive, but no phase 3 program or approval exists.
The scorecard
AT247 is specifically engineered for faster absorption than current rapid analogs and has positive phase 1 data, including pump-delivery testing.[2]
The formulation aims to front-load insulin exposure for meal physiology; detailed head-to-head commercial-label outcomes are not available.[3]
Faster absorption should reduce late insulin action, but clinically proven tail shortening is not established.[3]
Only early clinical datasets exist; day-to-day variability in broad real-world pump use is unproven.[2]
A faster profile could help exercise planning, but exercise-specific outcomes have not been reported.[1]
Insulins are scored relative to their role peers (see tags: rapid, ultra-rapid, basal, inhaled). A basal insulin's onset score compares it to other basals, not to mealtime insulins.
The full picture
AT247 is the U100 sibling to Arecor's concentrated AT278 program. It matters because current AID systems are held back by insulin pharmacology: algorithms can decide quickly, but injected insulin arrives slowly. AT247 is trying to shrink that lag. The limitation is development maturity: interesting early data, no late-stage T1D outcomes, and no approval path yet.
Coming soon
ETA · Phase 1 complete; no phase 3 or approval timeline announced
Sources
- [1]Arecor diabetes portfolio: AT247 and AT278 · manufacturer
- [2]Arecor commences US phase I trial of AT247 delivered by insulin pump · manufacturer · 2022-01-20
- [3]Arecor presents positive phase 1 clinical trial results for AT247 · conference · 2020-06-15